Literature DB >> 19369630

Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile.

Rosane De Oliveira Duarte Achcar1, Marina N Nikiforova, Samuel A Yousem.   

Abstract

Micropapillary lung adenocarcinoma (MPA) has been reported as an aggressive variant of adenocarcinoma, frequently manifesting at high stage with a poor prognosis. We analyzed the clinical and molecular profile of 15 primary MPAs for K-ras, EGFR, and BRAF mutations and performed fluorescence in situ hybridization for EGFR amplification. In our study, 11 (73%) of 15 MPAs harbored mutually exclusive mutations: 5 (33%) K-ras, 3 (20%) EGFR, and 3 (20%) BRAF. Mutations in all 3 genes occurred in patients with a smoking history and tumors with mucinous differentiation and secondary lepidic, acinar, and solid growth, suggesting that in a Western population, cytomorphologic correlation with genetic mutations is more unpredictable than in Japanese cohorts. We conclude that K-ras, EGFR, and BRAF mutations are disproportionately seen in adenocarcinomas of lung with a dominant micropapillary growth pattern compared with conventional adenocarcinoma in our institutional experience.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19369630     DOI: 10.1309/AJCPBS85VJEOBPDO

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  28 in total

1.  Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma.

Authors:  Song Gao; Seth Stein; Elena N Petre; Waleed Shady; Jeremy C Durack; Carole Ridge; Prasad Adusumilli; Natasha Rekhtman; Stephen B Solomon; Etay Ziv
Journal:  Cardiovasc Intervent Radiol       Date:  2017-08-02       Impact factor: 2.740

2.  BRAF mutations in non-small cell lung cancer.

Authors:  Peter P Luk; Bing Yu; Chiu Chin Ng; Belinda Mercorella; Christina Selinger; Trina Lum; Steven Kao; Sandra A O'Toole; Wendy A Cooper
Journal:  Transl Lung Cancer Res       Date:  2015-04

3.  Prognostic factors of patients with pathologic stage I lung adenocarcinoma.

Authors:  Ying-Yi Chen; Tsai-Wang Huang
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 4.  The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management.

Authors:  Yong Tang; Zhe He; Qihang Zhu; Guibin Qiao
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 5.  Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.

Authors:  Swaroop Revannasiddaiah; Priyanka Thakur; Bhaskar Bhardwaj; Sridhar Papaiah Susheela; Irappa Madabhavi
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 6.  Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts.

Authors:  Ming-Ching Lee; Kyuichi Kadota; Daniel Buitrago; David R Jones; Prasad S Adusumilli
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

7.  Expression level of CRKL and AXL combined with exon 19 deletion in EGFR and ALK status confer differential prognosis of lung adenocarcinoma subtypes.

Authors:  Yi-Ran Cai; Yu-Jie Dong; Hong-Bo Wu; Da-Ping Yu; Li-Juan Zhou; Dan Su; Li Zhang; Xue-Jing Chen
Journal:  Oncol Lett       Date:  2016-09-02       Impact factor: 2.967

8.  Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

Authors:  Stephanie Cardarella; Atsuko Ogino; Mizuki Nishino; Mohit Butaney; Jeanne Shen; Christine Lydon; Beow Y Yeap; Lynette M Sholl; Bruce E Johnson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

9.  Genetic alterations in lung adenocarcinoma with a micropapillary component.

Authors:  Masashi Furukawa; Shinichi Toyooka; Kouichi Ichimura; Hiromasa Yamamoto; Junichi Soh; Shinsuke Hashida; Mamoru Ouchida; Kazuhiko Shien; Hiroaki Asano; Kazunori Tsukuda; Shinichiro Miyoshi
Journal:  Mol Clin Oncol       Date:  2015-12-02

Review 10.  [Molecular pathology of the lungs. New perspectives by next generation sequencing].

Authors:  C Vollbrecht; K König; L Heukamp; R Büttner; M Odenthal
Journal:  Pathologe       Date:  2013-02       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.